Article Figures & Data
Figures
- FIGURE 1.
(A) Midsagittal 18F-fluoride PET image through lumbar vertebrae showing region of interest within vertebral bodies (at right is magnification of L1–L5 vertebral bodies, with squares indicating regions of interest). (B) Coronal image of pelvis and both proximal femurs (at bottom is magnification of left femoral neck, with square indicating region of interest).
- FIGURE 2.
Percentage changes in BSALP and NTx (A), SUV of lumbar spine and femoral neck (B), and BMD of lumbar spine and femoral neck (C) after alendronate treatment relative to baseline values. Percentage change in BSALP was significant at 6 and 12 mo; that of NTx was significant at 3, 6, and 12 mo. Percentage change in lumbar spine SUV was significant at 3 and 12 mo; that of femoral neck SUV was significant at 12 mo. Percentage change in BMD of lumbar spine was significantly different only between baseline and 12 mo of treatment. *P < 0.05. **P < 0.01. FN = femoral neck; L = lumbar spine; Pre = pretreatment.
- FIGURE 3.
Correlations with lumbar spine SUV at baseline (top) and after 12 mo of treatment with alendronate (bottom). (A) BSALP correlated with SUV significantly at baseline (y = 68.7 − 8.0x, R = 0.51, n = 24, P < 0.05) but not at 12 mo. (B) No significant correlation was found between NTx and SUV either at baseline or at 12 mo. (C) A positive correlation that was found between BMD and SUV at baseline (y = 0.5 + 0.05x, R = 0.45, n = 24, P < 0.05) disappeared after treatment with alendronate for 12 mo. BCE = bone collagen equivalent; Cr = creatinine.
Tables
Characteristic Mean SD Range Age (y) 59.7 6.3 50–69 Time since menopause (y) 9.8 6.0 3–19 Weight (kg) 53.0 8.5 40–70 Height (cm) 153.0 4.7 144–164 Prednisolone equivalent (mg/d) 13.7 2.3 11–18 Lumbar spine BMD (g/cm2) 0.78 0.08 0.56–0.91 Lumbar spine T-score 2.2 0.90 4.43–0.16 Femoral neck BMD (g/cm2) 0.72 0.09 0.54–0.95 Femoral neck T-score 2.9 0.88 -4.8–0.6 BSALP (U/L) 27.0 11.3 9.6–56.7 NTx (nmol BCE/nmol Cr) 56.5 22.3 20.1–97 Lumbar spine SUV 5.2 0.72 4.23–6.95 Femoral neck SUV 2.5 0.47 1.58–3.35 BCE = bone collagen equivalent; Cr = creatinine.
Marker T-score > −2.5 T-score ≤ −2.5 P Number of patients 14 10 – Lumbar spine BMD (g/cm2) 0.88 (0.14) 0.71 (0.07) <0.01 Lumbar spine T-score −1.2 (1.2) −3.0 (0.59) <0.01 Femoral neck BMD (g/cm2) 0.77 (0.07) 0.63 (0.06) <0.01 Femoral neck T-score −2.4 (0.64) −3.7 (0.67) <0.01 BSALP (U/L) 24.2 (9.0) 32.0 (13.7) 0.160 NTx (nmol BCE/nmol Cr) 53.8 (21.8) 56.2 (21.1) 0.802 Lumbar spine SUV 5.9 (1.3) 4.9 (0.46) <0.05 Femoral neck SUV 2.4 (0.60) 2.6 (0.58) 0.641 BCE = bone collagen equivalent; Cr = creatinine.
Data are mean followed by SD in parentheses.
Marker Baseline Treatment with alendronate 3 mo 6 mo 12 mo BSALP (U/L) 27.0 (11.3) 22.6 (8.7) 19.7 (9.0)* 18.5 (6.6)* NTx (nmol BCE/nmol Cr) 56.5 (22.4) 26.2 (8.4)† 22.3 (8.0)† 20.5 (6.2)† Lumbar spine SUV 5.2 (0.72) 4.8 (0.48)* 4.4 (0.48)† Femoral neck SUV 2.5 (0.47) 2.2 (0.53) 1.8 (0.51)† Lumbar spine BMD (g/cm2) 0.78 (0.079) 0.80 (0.076) 0.84 (0.077)* Lumbar spine T-score −2.2 (0.90) −2.0 (0.73) −1.6 (0.75)* Femoral neck BMD (g/cm2) 0.72 (0.093) 0.72 (0.090) 0.77 (0.084) Femoral neck T-score −2.9 (0.88) −2.7 (0.85) −2.3 (0.74)
Jump to section
Related Articles
Cited By...
- Dynamic Bone Imaging with 99mTc-Labeled Diphosphonates and 18F-NaF: Mechanisms and Applications
- The Precision and Sensitivity of 18F-Fluoride PET for Measuring Regional Bone Metabolism: A Comparison of Quantification Methods
- Small-Animal PET/CT Assessment of Bone Microdamage in Ovariectomized Rats
- SNM Practice Guideline for Sodium 18F-Fluoride PET/CT Bone Scans 1.0
- Quantitative Radionuclide Studies of Bone